CUE NASDAQ
Cue Biopharma, Inc.
1W: -18.6%
1M: -5.2%
3M: -21.3%
YTD: +152.7%
1Y: +17.8%
3Y: -65.1%
5Y: -94.1%
$25.57
+0.32 (+1.27%)
Weekly Expected Move ±18.5%
$16
$21
$26
$30
$35
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
-0.90
Bearish
0 bullish
0 neutral
1 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (46)
165,177 Cue Biopharma, Inc. $CUE Shares Sold by State Street Corp
Cue Biopharma plummets on phase 2 data for chronic spontaneous urticaria asset
At a glance: stocks gapping up premarket
Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria
Cue Biopharma is a new Buy at B. Riley on valuation
BlackRock Inc. Acquires New Holdings in Cue Biopharma, Inc. $CUE
Cue Biopharma GAAP EPS of -$24.14 misses by $22.23, revenue of $7.88M beats by $5.78M
Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Cue Biopharma to raise $50M in oversubscribed private placement
Cue Biopharma Announces Board Transition and Addition of New Directors with Continued Company Evolution
Cue Biopharma to Present at the 2026 Jefferies Global Healthcare Conference
Cue Biopharma to Present at the 2026 Jefferies Global Healthcare Conference
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
Why Twilio Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
Cue Biopharma Stock Surges Over 65% Overnight: Why Is It Moving?
12 Health Care Stocks Moving In Thursday's After-Market Session
Cue Biopharma Announces $30 Million Private Placement
Cue Biopharma Expands Pipeline with Exclusive License from Ascendant Health Sciences Ltd. for Clinical-Stage Dual-Mechanism Anti-IgE Antibody
Cue Biopharma Names Shao-Lee Lin M.D., Ph.D., CEO, President and Board Director to Lead Continued Growth and Transformation into a Clinical-Stage Company
Cue Biopharma (NASDAQ:CUE) Shares Gap Down – Should You Sell?
What's Behind The Drop In Cue Biopharma Stock Today?
Cue Biopharma falls 25% despite 1-for-30 reverse split plan
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
Cue Biopharma Receives $7.5M Milestone Payment From Boehringer Ingelheim
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
Cue Biopharma names Lucinda Warren as interim CEO
Cue Biopharma Announces CEO Transition
Cue Biopharma to Host Virtual R&D Day Event on April 7, 2026
Cue Biopharma GAAP EPS of $0.01, revenue of $21.94M
12 Health Care Stocks Moving In Monday's After-Market Session
Cue Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
Cue Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
12 Health Care Stocks Moving In Friday's Pre-Market Session
Cue Biopharma Announces Preclinical Safety and Tolerability Data for CUE-401 for the Treatment of Autoimmune and Inflammatory Diseases
Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Financial and Business Officer
Cue Biopharma (NASDAQ:CUE) Shares Up 34.8% – What’s Next?
Cue Biopharma Announces Pricing of $10 Million Public Offering
Cue Biopharma Announces Proposed Public Offering